Pharmacokinetics, Safety and Efficacy of Intravenous Vedolizumab in Paediatric Patients with Ulcerative Colitis or Crohn’s Disease: Results from the Phase 2 HUBBLE Study

BACKGROUND AND AIMS: To date, there are no systematic pharmacokinetic [PK] data on vedolizumab in paediatric inflammatory bowel disease [IBD]. We report results from HUBBLE, a dose-ranging, phase 2 trial evaluating the PK, safety and efficacy of intravenous vedolizumab for paediatric IBD. METHODS: E...

Descripción completa

Detalles Bibliográficos
Autores principales: Hyams, Jeffrey S, Turner, Dan, Cohen, Stanley A, Szakos, Erzsébet, Kowalska-Duplaga, Kinga, Ruemmele, Frank, Croft, Nicholas M, Korczowski, Bartosz, Lawrence, Promise, Bhatia, Siddharth, Kadali, Harisha, Chen, Chunlin, Sun, Wan, Rosario, Maria, Kabilan, Senthil, Treem, William, Rossiter, Guillermo, Lirio, Richard A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9426668/
https://www.ncbi.nlm.nih.gov/pubmed/35301512
http://dx.doi.org/10.1093/ecco-jcc/jjac036

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9426668/
https://www.ncbi.nlm.nih.gov/pubmed/35301512
http://dx.doi.org/10.1093/ecco-jcc/jjac036

Ejemplares similares